Pricing Log in Create free account
Saturday 17 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

255.55 2.27 +0.90%
Market cap
$610.4B
P/E
29.6×
Fwd P/E
24.9×
Dividend yield
2.07%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Johnson & Johnson (JNJ) Book value per share

Alert me on Book value per share

Johnson & Johnson's book value per share at the end of fiscal 2025 was 33.9×, up 14.1% from 29.7× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 35.3×. Over the past ten years it has ranged from 22.3× (fiscal 2018) to 33.9× (fiscal 2025) — the current reading is the highest in ten years. Johnson & Johnson ranks 3rd of 21 Drug Manufacturers General companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 33.9× 14.06%
FY2024 29.7× 9.40%
FY2023 27.1× (7.21%)
FY2022 29.3× 4.03%
FY2021 28.1× 17.01%
FY2020 24.0× 6.90%
FY2019 22.5× 0.90%
FY2018 22.3× (0.29%)
FY2017 22.3× (13.13%)
FY2016 25.7× 0.22%

Quarterly newest first

Period Book value per share Change
Jun 2026 35.3× 4.72%
Mar 2026 33.7× (0.49%)
Dec 2025 33.9× 2.90%
Sep 2025 32.9× 0.94%
42 more quarters

Against its own ten years

Low 22.3× High 33.9×
Ten-year median 25.7×
Current reading's percentile 100

Book value per share against peers

Company Book value per share
LLY Eli Lilly and Company compare 38.0×
JNJ Johnson & Johnson 35.3×
AZN AstraZeneca PLC compare 32.5×
NVS Novartis AG compare 22.0×
AMGN Amgen Inc. compare 21.6×
MRK Merck & Co., Inc. compare 17.0×
PFE Pfizer Inc. compare 15.0×
GILD Gilead Sciences, Inc. compare 9.4×
ABBV AbbVie Inc. compare −3.3×

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on JNJ